rapid
respons
strategi
understand
emerg
viral
pathogenesi
test
vaccin
therapeut
restrict
epidem
spread
prevent
morbid
mortal
essenti
earli
phase
epidem
influenza
virus
coronavirus
cov
emerg
human
pathogen
caus
sever
respiratori
infect
often
culmin
acut
respiratori
distress
syndrom
ard
endstag
lung
diseas
associ
high
mortal
rate
cov
envelop
virus
belong
order
nidoviral
contain
largest
known
positivesens
rna
genom
kb
cov
replic
effici
wide
rang
mammalian
host
divid
three
major
genera
alphacoronaviru
betacoronaviru
gammacoronaviru
within
genera
cov
divid
subgroup
b
includ
human
cov
caus
mild
moder
respiratori
diseas
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
epidem
result
agedepend
mortal
recent
anoth
call
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
middl
east
april
caus
pneumonia
ard
well
renal
failur
patient
date
merscov
spread
eight
countri
implic
case
report
death
mortal
rate
approach
especi
elderli
patient
merscov
share
close
phylogenet
relationship
pipistrellu
bat
coronaviru
btcov
strain
tylonycteri
btcov
strain
three
virus
classifi
subgroup
see
fig
supplement
materi
bat
serv
reservoir
circul
swarm
zoonot
virus
readili
posit
directli
cross
speci
barrier
infect
human
popul
sarscov
believ
origin
close
relat
bat
predecessor
strain
similar
btcov
although
exact
precursor
viru
identifi
zoonot
sourc
merscov
remain
unknown
recent
report
identifi
presenc
close
amino
acid
similar
merscov
nycteri
pipistrellu
bat
speci
anoth
studi
describ
close
similar
merscov
btcov
homolog
virus
share
high
degre
amino
acid
sequenc
similar
across
import
replicas
protein
target
proteas
also
known
nonstructur
protein
polymeras
proofread
exonucleas
well
nucleocapsid
n
protein
recent
find
suggest
protein
coevolv
within
subgroup
cov
make
attract
target
test
model
close
relat
subgroup
lack
small
anim
model
merscov
limit
understand
pathogenesi
belong
subgroup
therebi
hamper
develop
vaccin
therapeut
btcov
share
high
degre
genet
sequenc
ident
merscov
replicas
target
n
gene
therefor
develop
small
anim
model
assist
us
identifi
viral
determin
pathogenesi
virul
explor
possibl
vaccineinduc
eosinophilia
merscov
vaccin
identifi
antivir
broad
activ
subgroup
strain
furthermor
date
subgroup
bat
cov
cultur
vitro
avail
infecti
clone
virus
help
us
dissect
common
evolutionari
relationship
among
pathogen
cov
strain
report
vitro
reconstruct
biolog
character
use
revers
genet
syntheticgenom
design
infecti
clone
btcov
icbtcov
contain
ectodomain
sar
spike
protein
btcov
show
btcov
replic
effici
demonstr
small
molecul
inhibitor
target
effect
inhibit
btcov
merscov
replic
cell
cultur
addit
report
btcov
replic
high
titer
young
age
mice
caus
lifethreaten
diseas
viru
replic
diseas
depend
presenc
mous
angiotensinconvert
enzym
receptor
immunohistochemistri
stain
demonstr
presenc
viral
antigen
epitheli
cell
line
small
airway
alveoli
btcov
replic
inhibit
sarscov
proteinbas
vaccin
sensit
vaccin
base
protein
subgroup
cov
unlik
mice
vaccin
sarscov
nexpress
venezuelan
equin
enceph
vee
viru
replicon
particl
vrp
sever
eosinophil
immun
patholog
observ
follow
btcov
challeng
anim
vaccin
vrp
express
n
merscov
n
support
develop
kill
recombin
protein
vaccin
merscov
vivo
passag
btcov
young
mice
result
select
mouseadapt
strain
btcov
replic
effici
caus
signific
clinic
diseas
progress
interstiti
pneumonia
diffus
alveolar
damag
dad
age
mice
mutat
open
read
frame
protein
confer
increas
virul
mice
taken
togeth
result
illustr
util
syntheticgenomicsbas
platform
rapidli
gener
set
relat
zoonot
virus
identifi
viral
determin
increas
virul
assist
develop
broadli
activ
drug
preview
potenti
vaccinerel
complic
could
provid
invalu
direct
investig
earli
phase
epidem
previous
describ
synthet
reconstruct
noncultivat
viru
btcov
phylogenet
studi
indic
btcov
close
relat
merscov
use
publish
sequenc
inform
synthes
infecti
molecular
clone
btcov
icbtcov
genom
viru
synthes
six
contigu
cdna
fragment
shown
fig
subclon
flank
class
ii
restrict
endonucleas
allow
direct
assembl
fulllength
cdna
genom
encod
start
end
poli
tract
end
fulllength
rna
gener
use
vitro
transcript
ligat
cdna
upon
electropor
vero
cell
fulllength
rna
infecti
viru
recover
despit
robust
express
btcov
n
subgenom
mrna
day
postelectropor
see
fig
supplement
materi
passag
cell
cultur
supernat
result
diminish
viral
subgenom
n
mrna
express
time
eventu
recombin
viru
went
extinct
cultur
fig
previou
studi
group
other
demonstr
substitut
receptor
bind
domain
rbd
sarscov
glycoprotein
enabl
effici
vivo
replic
btcov
enabl
recoveri
btcov
cell
cultur
adopt
similar
strategi
assembl
recombin
chimer
btcov
encod
glycoprotein
ectodomain
btcov
fig
yellow
sarscov
substitut
chang
tyr
posit
fig
asterisk
previous
shown
enhanc
replic
mice
also
includ
spike
gene
btcov
chimer
viru
recov
electropor
fulllength
transcript
vero
cell
vero
cell
btcov
replic
kinet
similar
merscov
merscov
saudi
arabian
isol
sarscov
earlier
time
point
achiev
peak
titer
h
pi
fig
c
cytopatholog
character
fusion
cell
start
h
pi
cell
death
note
h
pi
btcov
stabl
cell
cultur
indic
realtim
pcr
analysi
express
passag
six
see
fig
supplement
materi
btcov
replic
kinet
similar
merscov
england
isol
merscov
eng
fig
interestingli
mark
differ
viru
replic
fig
cell
lung
epitheli
cell
line
btcov
replic
lower
titer
either
merscov
isol
sarscov
although
specul
growth
differ
support
lowlevel
express
n
protein
fig
later
time
point
could
reflect
differ
sensit
interferon
cell
effici
cov
replic
transcript
involv
product
nest
set
subgenom
mrna
northern
blot
analysi
vero
cell
infect
btcov
reveal
eight
subgenom
mrna
fig
predict
open
read
frame
encod
mrna
indic
tabl
supplement
materi
next
character
express
structur
protein
cell
infect
btcov
use
antisera
mice
vaccin
vrp
express
btcov
n
protein
demonstr
btcov
infect
vero
cell
produc
discret
n
protein
band
predict
molecular
mass
kda
cell
lysat
fig
polyclon
serum
specif
sarscov
identifi
glycoprotein
along
smaller
subunit
kda
faster
migrat
band
lysat
infect
vero
cell
fig
consist
express
sarscov
ectodomain
recombin
btcov
contrast
polyclon
serum
rais
btcov
recogn
protein
data
shown
support
earlier
observ
major
antibodi
epitop
protein
like
concentr
n
terminu
n
protein
btcov
share
sequenc
ident
merscov
btcov
n
protein
identifi
possibl
crossreact
btcov
gener
mous
polyclon
sera
use
vrp
express
n
protein
btcov
merscov
isol
demonstr
sera
recogn
btcov
n
protein
fig
e
taken
togeth
result
demonstr
presenc
conserv
polyclon
antibodi
epitop
subgroup
cov
n
protein
small
molecul
inhibitor
target
effici
block
sarscov
replic
sequenc
similar
protein
merscov
btcov
well
posit
identifi
broadli
reactiv
group
proteas
inhibitor
import
signific
function
regulatori
differ
protein
differ
subgroup
strong
conserv
determin
within
subgroup
therefor
analyz
whether
small
molecul
inhibitor
could
inhibit
replic
btcov
merscov
cell
cultur
enzym
purifi
use
publish
method
detail
method
text
supplement
materi
result
high
yield
mgliter
puriti
inhibit
assay
conduct
use
fluorimetr
substrat
describ
previous
potent
inhibit
btcov
activ
inhibit
constant
ki
mean
standard
deviat
vero
cell
pretreat
concentr
inhibitor
infect
btcov
merscov
multipl
infect
moi
viral
titer
determin
h
postinfect
pi
importantli
complet
block
viral
replic
earli
time
point
reduc
btcov
merscov
replic
h
pi
fig
e
reduc
virusinduc
cytopatholog
infect
cell
fig
thu
small
molecul
inhibitor
effect
reduc
replic
multipl
subgroup
cov
strain
examin
whether
btcov
replic
caus
diseas
mice
intranas
infect
young
old
balbc
mice
pfu
viru
btcov
caus
weight
loss
young
anim
age
balbc
mice
experienc
weight
loss
day
pi
fig
agedmous
model
clinic
sign
diseas
includ
lethargi
ruffl
fur
mildli
labor
breath
pattern
importantli
young
age
mice
viru
replic
pfug
lung
day
pi
fig
weight
loss
patholog
chang
note
mockinfect
young
age
anim
data
shown
substitut
sarscov
ectodomain
enhanc
bind
mous
receptor
infect
mice
btcov
assess
whether
requir
viru
entri
diseas
weight
loss
viru
replic
observ
mice
fig
b
clearli
identifi
requir
mous
btcov
entri
replic
diseas
although
littl
patholog
note
young
infect
anim
age
mice
develop
moresever
airway
diseas
perivascular
peribronchi
cuf
pneumonia
day
pi
airway
diseas
fig
bottom
includ
denud
region
airway
epithelium
debri
lumen
small
airway
peribronchi
cuf
increas
number
neutrophil
monocyt
perivascular
cuf
also
evid
larg
number
infiltr
neutrophil
monocyt
anim
develop
focal
region
sever
pneumonia
accompani
edemafil
alveoli
consist
earli
acut
dad
fig
bottom
identifi
cellular
target
immunohistochemistri
polyclon
serum
n
protein
perform
lung
section
young
age
mice
seen
sarscov
btcov
antigen
abund
airway
epitheli
cell
epitheli
cell
featur
characterist
type
ii
pneumocyt
alveoli
fig
stain
note
mockinfect
lung
fig
top
bottom
far
right
btcov
harbor
sarscov
ectodomain
evalu
whether
sarscov
sexpress
vrpbase
vaccin
would
provid
protect
virusinduc
diseas
young
age
mice
mock
vaccin
vee
viru
adjuv
particl
vap
vaccin
vrp
express
sarscov
glycoprotein
challeng
pfu
btcov
vaccin
age
anim
complet
protect
virusinduc
weight
loss
fig
viral
replic
lung
significantli
diminish
log
day
clear
day
pi
fig
contrast
viral
replic
detect
young
mice
vaccin
sarscov
sexpress
vrp
see
fig
supplement
materi
demonstr
complet
protect
consist
observ
plaqu
reduct
neutral
test
titer
btcov
vaccin
young
age
anim
respect
fig
furthermor
polyclon
sera
n
protein
neutral
btcov
fig
result
consist
idea
cov
n
protein
repres
princip
determin
protect
humor
immun
hightit
challeng
determin
whether
vrp
vaccin
express
protein
group
btcov
merscov
provid
crossprotect
btcov
replic
vivo
analysi
viral
replic
day
pi
indic
none
vaccin
elicit
crossprotect
see
fig
supplement
materi
result
consist
recent
report
show
absenc
crossneutr
use
sarscov
sspecif
antibodi
fulllength
merscov
rbd
previou
studi
group
other
reveal
immunemedi
patholog
lung
mice
immun
n
proteinbas
subunit
vaccin
doubli
inactiv
sarscov
vaccin
subsequ
challeng
homolog
heterolog
virus
immunemedi
patholog
also
note
inactiv
measl
respiratori
syncyti
viru
rsv
vaccin
character
presenc
high
number
pulmonari
eosinophil
challeng
potenti
pose
signific
barrier
develop
vaccin
emerg
cov
infect
importantli
btcov
n
protein
ident
merscov
n
share
crossreact
epitop
merscov
replic
mice
btcov
recombin
viru
offer
uniqu
heterolog
challeng
model
assess
whether
group
n
proteincontain
vaccin
might
elicit
pulmonari
immun
patholog
character
increas
eosinophilia
upon
challeng
young
mice
mock
immun
vap
prime
boost
vrp
express
merscov
n
btcov
n
subsequ
challeng
btcov
appreci
weight
loss
observ
group
fig
none
vaccin
provid
protect
viru
replic
measur
day
pi
fig
signific
increas
number
eosinophil
lung
day
pi
note
mice
immun
either
merscov
n
btcov
n
compar
level
eosinophil
lung
mockimmun
anim
p
determin
tukey
multiplecomparison
test
fig
analysi
histopatholog
section
also
reveal
signific
increas
number
eosinophil
mockimmun
n
proteinimmun
group
data
shown
signific
increas
note
monocyt
monocytederiv
dendrit
cell
neutrophil
nvaccin
mockvaccin
group
either
see
fig
supplement
materi
howev
signific
increas
b
cell
p
cell
p
mockimmun
n
vaccineimmun
anim
fig
f
consist
find
cell
lysatebas
enzymelink
immunosorb
assay
elisa
n
merscov
n
sera
bound
appropri
recombin
protein
express
vrp
indic
induct
antigenspecif
antibodi
fig
taken
togeth
result
demonstr
vrpvector
n
merscov
nbase
vaccin
elicit
signific
eosinophilia
homolog
heterolog
challeng
support
develop
merscov
vaccin
although
glycoprotein
critic
determin
crossspeci
transmiss
addit
mutat
across
genom
shown
contribut
host
switch
increas
diseas
sever
identifi
potenti
virul
allel
btcov
serial
passag
btcov
lung
balbc
mice
interv
viru
passag
btcov
mous
adapt
plaqu
purifi
use
inocul
young
age
anim
btcov
caus
signific
weight
loss
young
mice
caus
weight
loss
age
mice
fig
viru
titer
lung
significantli
increas
young
age
anim
day
pi
pfug
pfug
respect
fig
although
young
anim
exhibit
signific
increas
patholog
compar
mice
inocul
nonadapt
strain
fig
age
anim
develop
acut
interstiti
pneumonia
fibrin
deposit
hyalin
membran
format
fig
genom
sequenc
comparison
sequenc
parent
viru
reveal
chang
gene
result
mous
adapt
fig
b
top
noteworthi
frameshift
mutat
result
truncat
polyprotein
insert
nucleotid
g
bp
fig
top
furthermor
viru
also
detect
blood
day
pi
pfuml
organ
test
brain
liver
spleen
fig
bottom
recent
studi
anthoni
et
al
estim
presenc
approxim
differ
virus
circul
mammalian
zoonot
reservoir
potenti
cross
speci
barrier
emerg
new
human
pathogen
among
coronavirus
high
rna
recombin
frequenc
coupl
exist
interchang
domain
suggest
zoonot
strain
like
pois
crossspeci
transmiss
event
human
popul
studi
articul
strategi
would
enabl
rapid
develop
therapeut
target
evalu
vaccin
futur
emerg
zoonot
cov
bioprepared
platform
includ
panel
recombin
alpha
beta
gammacoronavirus
target
therapeut
vaccin
evalu
provid
strategi
rapidli
identifi
drug
therapeut
potenti
futur
emerg
zoonot
cov
previou
studi
shown
felin
murin
ectodomain
andor
rbd
group
cov
glycoprotein
interchang
preemerg
sarslik
cov
group
strain
broad
receptor
specif
recent
isol
bat
seem
like
similar
group
strain
exist
broad
host
rang
phenotyp
well
addit
antigen
distanc
minim
crossneutr
phenotyp
seen
across
within
group
strain
demonstr
inher
vulner
current
vaccin
therapeut
design
strategi
focu
singl
emerg
isol
control
purpos
rather
synthet
resurrect
group
strain
batsrbd
spike
rbd
sarscov
merscovlik
group
btcov
isol
provid
crucial
reagent
identifi
broadspectrum
antivir
address
target
issu
vaccin
design
btcov
merscov
share
high
sequenc
ident
across
import
replicas
protein
target
zoonot
virus
difficult
cultur
usual
exist
sequenc
signatur
repositori
databas
advent
synthet
biolog
provid
approach
resurrect
repres
strain
highli
heterogen
pool
consequ
potenti
risk
versu
benefit
experi
plan
contain
recombin
virus
discuss
detail
univers
north
carolina
institut
biosafeti
committe
advanc
experi
similar
previou
result
subgroup
btcov
strain
recombin
btcov
replic
spread
effici
cell
suggest
entri
block
observ
could
reflect
low
level
lack
appropri
receptor
express
andor
critic
entri
cofactor
cathepsin
proteas
use
chimer
btcov
viru
previous
demonstr
rbd
sarscov
protein
alon
suffici
bind
mous
enabl
viru
replic
mice
inclus
mouseadapt
substitut
enhanc
btcov
viru
replic
diseas
sever
agedanim
model
sarscov
recombin
virus
amino
acid
substitut
suffici
produc
sever
diseas
age
balbc
mous
model
btcov
attempt
replac
put
rbd
sarscov
rbd
unsuccess
like
reflect
high
antigen
distanc
structur
incompat
hinder
genet
exchang
domain
subgroup
glycoprotein
support
earlier
work
mous
hepat
viru
felin
coronaviru
introduc
sar
glycoprotein
ectodomain
substitut
btcov
genom
btcov
recombin
chimer
viru
isol
capabl
product
infect
cultur
young
age
balbc
mice
btcov
replic
effici
multipl
cell
type
use
mous
entri
mice
viru
replic
effici
reduc
interferoncompet
cell
vero
cell
similar
result
sarscov
suggest
possibl
limit
control
cellintrins
immun
mechan
report
sarscov
interest
gene
group
strain
like
merscov
close
relat
encod
interferon
antagonist
activ
detect
use
report
assay
use
revers
genet
group
other
delet
interferon
antagonist
merscov
littl
effect
viru
growth
vitro
btcov
molecular
clone
would
enabl
dissect
relat
interferon
antagonist
activ
accessori
orf
group
cov
identifi
common
uniqu
pathway
regul
innat
immun
respons
human
cell
noteworthi
essenti
replic
either
merscov
btcov
infect
cell
eight
subgenom
mrna
detect
northern
blot
assay
consist
predict
orf
genbank
indic
success
replic
transcript
cov
includ
btcov
merscov
sar
cov
use
consensu
acgaa
transcript
regulatori
sequenc
tr
start
site
avail
full
panel
infecti
clone
allow
us
engin
recombin
reversionproof
genom
rewir
tr
site
previous
describ
group
n
glycoprotein
recogn
respect
polyclon
sera
crossreact
note
btcov
btcov
merscov
n
protein
demonstr
conserv
antibodi
epitop
differ
strain
data
suggest
recombin
n
protein
nspecif
antisera
use
diagnost
reagent
serolog
test
human
sera
direct
detect
merscov
group
cov
antigen
tissu
btcov
viru
contain
authent
set
subgroup
replicas
accessori
structur
protein
provid
robust
platform
evalu
breadth
activ
antivir
drug
group
cov
among
coronavirida
inhibitor
shown
success
inhibit
sarscov
replic
vitro
use
biochem
assay
candid
drug
inhibit
merscov
btcov
proteas
activ
reduc
merscov
btcov
replic
vitro
although
intact
monolay
observ
drugtreat
cell
h
pi
viru
titer
reduc
similar
differ
report
coronaviru
papainlik
proteas
plp
inhibitor
drug
might
slow
viru
growth
cycl
retard
develop
cytopath
effect
cpe
addit
block
effect
might
interact
host
protein
activ
viru
infect
prevent
cell
death
nevertheless
broad
therapeut
action
distant
group
cov
support
hypothesi
effect
inhibitor
activ
multipl
subgroup
cov
provid
potenti
candid
drug
futur
outbreak
like
requir
modif
improv
durabl
biodistribut
potenc
vivo
btcov
caus
diseas
age
young
balbc
mice
lead
weight
loss
day
pi
contrast
coronavirus
mous
hepat
viru
still
replic
produc
diseas
carcinoembryon
antigenrel
cell
adhes
molecul
anim
replic
pathogenesi
btcov
complet
depend
upon
presenc
mous
receptor
mice
clearli
show
weight
loss
evid
viru
replic
furthermor
presenc
viral
antigen
small
airway
epitheli
cell
alveolar
cell
morpholog
like
type
ii
pneumocyt
characterist
tropism
report
sarscov
infect
mice
primat
histopatholog
examin
demonstr
interstiti
pneumonia
age
anim
replic
phenotyp
seen
infect
wildtyp
mouseadapt
strain
sarscov
human
mice
basi
agerel
diseas
phenotyp
follow
sarscov
infect
link
alter
prostaglandin
express
lung
impair
dendrit
cell
migrat
result
diminish
cell
respons
studi
need
evalu
basi
increas
btcov
pathogenesi
agedanim
model
mous
adapt
btcov
result
increas
viral
replic
greater
virul
age
mice
addit
anim
develop
interstiti
pneumonia
hyalin
membran
format
mutat
gene
associ
increas
virul
phenotyp
age
mice
interestingli
evolut
gene
also
report
follow
sarscov
passag
mice
human
expand
epidem
suggest
play
critic
role
crossspeci
adapt
replic
pathogenesi
importantli
btcov
chimera
fulli
suscept
sarscov
sbase
vaccin
polyclon
serum
rais
sarscov
complet
neutral
viru
vitro
differ
neutral
titer
young
age
anim
like
reflect
gradient
immun
respons
occur
age
anim
follow
emerg
cov
infect
data
demonstr
glycoprotein
retain
key
neutral
epitop
critic
protect
immun
contrast
none
vrp
express
protein
btcov
btcov
merscov
confer
protect
vivo
demonstr
diverg
group
cov
protein
find
argu
vaccin
design
novel
emerg
cov
involv
protein
respect
viru
chimer
multival
vaccin
contain
neutral
epitop
protein
differ
cov
previou
studi
laboratori
other
indic
anim
immun
vector
inactiv
sarscov
ncontain
vaccin
develop
immunemedi
patholog
lung
follow
homolog
heterolog
challeng
reminisc
rsv
vaccinemedi
immun
patholog
immun
patholog
character
high
number
eosinophil
infiltr
lung
postchalleng
result
demonstr
vrp
vaccin
express
merscov
n
elicit
eosinophil
immun
patholog
follow
btcov
challeng
report
inactiv
sarscov
vaccin
contrast
alum
caus
immun
respons
vrp
vaccin
induc
robust
immun
respons
high
neutral
antibodi
titer
although
studi
interpret
caution
effect
inactiv
merscov
btcov
vaccin
induct
eosinophilia
follow
challeng
remain
test
vrp
vector
proven
success
human
clinic
trial
vee
viru
replic
success
sever
anim
speci
includ
hors
goat
sheep
given
high
seropreval
merscov
camel
potenti
role
camel
intermedi
reservoir
human
diseas
vrp
platform
describ
may
effect
merscov
vaccin
candid
use
camel
reservoir
speci
develop
infecti
clone
recombin
virus
emerg
zoonot
cov
expedit
rapid
test
antivir
vaccin
outbreak
situat
limit
current
approach
wildtyp
merscov
btcov
replic
mice
recent
demonstr
merscov
glycoprotein
bound
receptor
may
inspir
strategi
design
recombin
merscov
strain
replic
well
mice
use
btcov
illustr
util
synthet
genom
revers
genet
strategi
resurrect
emerg
zoonot
virus
vitro
valid
find
use
drug
vaccin
readili
appli
outbreak
situat
btcov
merscov
merscov
cultur
vero
cell
grown
dulbecco
modifi
eagl
medium
gibco
ca
fetalclon
ii
hyclon
south
logan
ut
gentamicinkanamycin
gibco
carlsbad
ca
growth
curv
vero
cell
perform
previous
describ
viru
cultiv
perform
biosafeti
level
laboratori
redund
fan
biosafeti
cabinet
personnel
wore
power
airpurifi
respir
breath
easi
tyvek
suit
apron
booti
doubl
glove
gene
encod
cov
n
protein
indic
synthes
bio
basic
inc
ontario
canada
packag
venezuelan
equin
enceph
vee
viru
replicon
particl
vrp
condit
use
attenu
vee
viru
structur
protein
helper
follow
vaccin
mous
polyclon
sera
gener
balbc
mice
neutral
assay
involv
merscov
isol
sarscov
use
mous
antisera
perform
describ
previous
western
blot
lysat
cell
infect
btcov
merscov
isol
prepar
h
pi
describ
previous
blot
probe
use
mous
polyclon
sera
indic
vero
cell
inocul
btcov
harvest
h
pi
trizol
reagent
invitrogen
northern
blot
analysi
describ
genom
subgenomelength
rna
perform
use
probe
n
gene
describ
previous
btcov
molecular
clone
design
base
consensu
sequenc
btcov
isol
avail
genbank
nucleotid
sequenc
access
number
gene
encod
btcov
protein
also
replac
fulllength
ectodomain
sarscov
protein
residu
use
previous
describ
strategi
mouseadapt
substitut
sarscov
spike
protein
also
includ
chimer
construct
promot
replic
mice
clone
design
btcov
wildtyp
viru
chimer
btcov
e
fragment
synthes
bio
basic
inc
ontario
canada
six
contigu
cdna
assembl
vitro
transcript
recombin
viru
recov
vero
cell
transfect
fulllength
transcript
previous
describ
detail
synthet
reconstruct
btcov
btcov
approv
univers
north
carolina
ibc
institut
biosafeti
committe
also
review
possibl
dual
use
research
concern
experi
undertaken
ibc
also
examin
manuscript
submiss
young
age
balbc
mice
purchas
harlan
lab
intranas
inocul
volum
contain
pfu
btcov
viru
infect
anim
monitor
weight
loss
morbid
clinic
sign
diseas
lung
titer
determin
plaqu
assay
adapt
mice
confer
serial
passag
lung
young
balbc
mice
week
old
interv
pi
describ
detail
previous
anim
hous
care
experiment
protocol
accord
univers
north
carolina
institut
anim
care
use
committe
iacuc
guidelin
lung
mice
infect
btcov
harvest
day
pi
formalin
fix
day
remov
paraffinembed
tissu
section
stain
hematoxylin
eosin
stain
lung
section
blind
score
patholog
chang
stain
viral
antigen
perform
describ
previous
use
polyclon
serum
n
protein
young
age
mice
receiv
left
footpad
prime
boost
pfu
differ
vrpbase
n
vaccin
venezuelan
equin
enceph
viru
adjuv
particl
vap
express
transgen
mockinfect
control
interv
prime
boost
week
boost
anim
move
facil
allow
acclim
week
challeng
btcov
young
anim
week
age
anim
month
old
time
challeng
young
balbc
mice
mock
immun
infecti
unit
vap
express
transgen
vaccin
vrp
encod
btcov
n
merscov
n
challeng
pfu
btcov
anim
weigh
monitor
clinic
symptom
daili
day
pi
mice
sacrif
isofluran
inhal
viabl
cell
popul
lung
prepar
stain
appropri
antibodi
sort
use
flow
cytometri
previous
describ
detail
